Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Synact Pharma - More than just RA

Planlagt Fastgjort Låst Flyttet Debatforum
0 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • N Offline
    N Offline
    Nijjam
    wrote on sidst redigeret af
    #1

    Hello. Any danish people invested in Synact? Thought i'd make a short brief of the company.
    Synact is a Swedish biotech listed on Nasdaq Stockholm, led by Danish CEO Jeppe Øvlesen and a team of experienced industry professionals.

    SynAct Pharma ($SYNACT.ST) is rapidly evolving from a single-asset RA company into a broad inflammation and resolution therapy platform.

    At its core is Resomelagon (AP1189), a first-in-class melanocortin agonist that doesn't suppress the immune system but instead actively resolves inflammation. This unique mechanism opens doors across autoimmune, infectious, and acute inflammatory diseases.

    Pipeline highlights:

    Rheumatoid Arthritis (RA): Phase 2b ADVANCE trial ongoing, targeting early, treatment-naïve patients. Resomelagon could become the first oral, non-steroidal alternative to corticosteroids.
    Trigger: Q1 2026

    Polymyalgia Rheumatica (PMR): Investigator-led study underway addressing a large unmet need for steroid-sparing therapies.
    Trigger: 2026 →

    Dengue Fever (RESOVIR-2, Phase II in Brazil): Potential breakthrough in a disease with no effective treatment.
    Trigger: 2026→

    COVID & viral inflammation: Positive proof-of-concept data supports host-directed anti-inflammatory potential.

    TXP platform: Proprietary peptide pipeline (TXP-11, others) broadening SynAct's reach into transplantation and acute immune disorders.

    SynAct recently announced a 10M SEK share buyback program, and with strong cash reserves to fund operations well into 2026-2027, plus expected soft funding collaborations in Latin America, the company is in a strong position to accelerate value creation over the coming quarters.
    ''Last patient in'' announcement should drop in the coming weeks.

    1 Reply Last reply
    0

    Hello! It looks like you're interested in this conversation, but you don't have an account yet.

    Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

    With your input, this post could be even better 💗

    Tilmeld Log ind

    • Log ind

    • Har du ikke en konto? Tilmeld

    • Login or register to search.
    • First post
      Last post
    0
    • Debatforum
    • Seneste
    • Populære
    • Bruger